Endo (ENDP) Has No Linden Care Exposure - RBC Capital

RBC Capital analyst Randall Stanicky said Endo International plc (NASDAQ: ENDP) has no Linden Care exposure. The firm retained a Top Pick rating and price target of $91.00.

"We have confirmed with ENDP that it has zero exposure while DEPO has informed us it has 1/2% revenue exposure to ESRX linked scripts through Linden Care, spread equally across ‎Gralise, Cambia and Lazanda.‎ Per our separate note, we believe the INSY exposure to ESRX scripts through Linden Care is about 1% of revenue."

For an analyst ratings summary and ratings history on Endo International plc click here. For more ratings news on Endo International plc click here.

Shares of Endo International plc closed at $55.57 yesterday.

You May Also Be Interested In

• Benchmark Reiterates Buy Rating on MiniMed Group (MMED)
• MarketAxess (MKTX) PT Lowered to $200 at UBS Following June Metrics Release
• BofA Securities Double Downgrades EHang Holdings (EH) to Underperform